Clinical trials: Heart Failure, Reduced Ejection Fraction
Heart Failure
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.
- Trial name
- PARTHENON (NCT02957409)
- Testing
- sacubitril/valsartan
- Where
- 32 sites in Canada
- Volunteers
- 1,009 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure, Left Bundle Branch Block
MIRACLE EF Clinical Study
This study is looking at whether the electrical treatment provided by a special type of pacemaker called a Cardiac Resynchronization Therapy (CRT) pacemaker may keep a patient's heart failure from getting worse.
- Conditions
- Congestive Heart Failure, Left Bundle Branch Block, Systolic Heart Failure
- Trial name
- MIRACLE EF (NCT01735916)
- Testing
- CRT-P Implant, CRT-P OFF
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 44 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.
Heart Failure
ALLEVIATE-HFrEF Study
Patients with heart failure and reduced left ventricular ejection fraction (HFrEF, EF ≤ 40%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using…
- Trial name
- NCT05133089
- Testing
- ALV1 System
- Where
- Georgia
- Volunteers
- 5 people
- Sponsor
- Alleviant Medical, Inc.
Heart Failure With Reduced Ejection Fraction
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv…
- Trial name
- METEORIC-HF (NCT03759392)
- Testing
- Omecamtiv Mecarbil
- Where
- 81 sites in United States, Canada and 7 more
- Volunteers
- 276 people
- Sponsor
- Cytokinetics
Heart Failure With Reduced Ejection Fraction
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with LCZ696 in HFrEF patients following stabilization after an ADHF episode.
- Trial name
- TRANSITION (NCT02661217)
- Testing
- LCZ696
- Where
- 152 sites in Argentina, Belgium and 17 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure, Heart Failure
AB-1002 in Patients With Class III Heart Failure
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart…
- Conditions
- Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases
- Trial name
- NAN-CS101 (NCT04179643)
- Testing
- 3 x 10e13vg AB-1002
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- AskBio Inc
Chronic Heart Failure
Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
Multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on serum NT-proBNP, as well as safety in patients…
- Trial name
- NCT01439789
- Testing
- rhNRG-1
- Where
- 21 sites in China
- Volunteers
- 146 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Chronic Heart Failure
Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
- Trial name
- NCT01541202
- Testing
- rhNRG-1
- Where
- 46 sites in China
- Volunteers
- 679 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Heart Failure, Cardiac Failure
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function
The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.
- Conditions
- Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction
- Trial name
- NCT03357731
- Testing
- HNO Donor, Nitroglycerin (NTG)
- Where
- 18 sites in United States, Japan and 2 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure
Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.
The study is a cohort observational, retrospective, non-interventional study.
- Trial name
- NCT05448872
- Testing
- Sacubitril/Valsartan
- Where
- Italy
- Volunteers
- 924 people
- Sponsor
- Novartis Pharmaceuticals
HFrEF - Heart Failure With Reduced Ejection Fraction
Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- Vsling III (NCT06002386)
- Testing
- Vsling
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Cardiac Success
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systemic Inflammation
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks…
- Trial name
- ATHENA (NCT06200207)
- Testing
- Ziltivekimab
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 673 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Reduced Ejection Fraction
Effect of the MobiusHD® in Patients With Heart Failure
This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and effectiveness of the MobiusHD® in patients with heart failure and reduced ejection fraction.
- Trial name
- HF-FIM (NCT04590001)
- Testing
- MobiusHD
- Where
- 17 sites in Australia, Canada and 3 more
- Volunteers
- 50 people
- Sponsor
- Vascular Dynamics, Inc.
Heart Failure
Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)
The purpose of this study was to generate effectiveness data of Angiotensin receptor neprilysin inhibitor (ARNI), in the Chinese Heart failure with reduced ejection fraction (HFrEF) patients with implantable cardioverted…
- Trial name
- RHYTHM (NCT04491136)
- Testing
- ACEI/ARB, ARNI
- Where
- 23 sites in China
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure
REDUCE LAP-HFREF TRIAL
The objective of this pilot study is to evaluate the safety and performance of implanting the IASD® System II in Heart Failure patients with reduced ejection fraction and elevated left sided filling pressures, who remain…
- Trial name
- NCT03093961
- Testing
- IASD implant
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Corvia Medical